DK2378290T3 - Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs using pro-vasopressin, especially copeptin or neurophysin II - Google Patents
Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs using pro-vasopressin, especially copeptin or neurophysin II Download PDFInfo
- Publication number
- DK2378290T3 DK2378290T3 DK11170807.9T DK11170807T DK2378290T3 DK 2378290 T3 DK2378290 T3 DK 2378290T3 DK 11170807 T DK11170807 T DK 11170807T DK 2378290 T3 DK2378290 T3 DK 2378290T3
- Authority
- DK
- Denmark
- Prior art keywords
- infections
- lungs
- diagnosis
- chronic diseases
- copeptin
- Prior art date
Links
- 101800000115 Copeptin Proteins 0.000 title claims abstract description 51
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 48
- 208000017667 Chronic Disease Diseases 0.000 title claims abstract description 42
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 title claims abstract 7
- 210000004072 lung Anatomy 0.000 title claims description 42
- 238000003745 diagnosis Methods 0.000 title claims description 38
- 238000013517 stratification Methods 0.000 title claims description 32
- 102000002710 Neurophysins Human genes 0.000 title claims description 23
- 108010018674 Neurophysins Proteins 0.000 title claims description 23
- 210000002345 respiratory system Anatomy 0.000 title claims 10
- 229960003726 vasopressin Drugs 0.000 title description 5
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 title description 4
- 108010004977 Vasopressins Proteins 0.000 title description 4
- 102000002852 Vasopressins Human genes 0.000 title description 4
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 42
- 238000004393 prognosis Methods 0.000 claims abstract description 12
- 238000001514 detection method Methods 0.000 claims abstract description 7
- 108010048233 Procalcitonin Proteins 0.000 claims description 25
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims description 25
- 206010035664 Pneumonia Diseases 0.000 claims description 24
- 239000003550 marker Substances 0.000 claims description 22
- 238000000338 in vitro Methods 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 9
- 102100032752 C-reactive protein Human genes 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 6
- 238000013399 early diagnosis Methods 0.000 claims description 6
- 238000003748 differential diagnosis Methods 0.000 claims description 5
- 201000000306 sarcoidosis Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- -1 IL-6 Chemical compound 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000013610 patient sample Substances 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 229910052743 krypton Inorganic materials 0.000 claims 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000009123 therapy by drug Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 21
- 108010064409 proAVP hormone Proteins 0.000 abstract description 2
- 208000032376 Lung infection Diseases 0.000 abstract 1
- 102400000060 Copeptin Human genes 0.000 description 44
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 14
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 5
- 108010091794 preprovasopressin Proteins 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 3
- 230000009798 acute exacerbation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 108010040956 Ala-Asp-Glu-Leu Proteins 0.000 description 2
- DHBKYZYFEXXUAK-ONGXEEELSA-N Ala-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 DHBKYZYFEXXUAK-ONGXEEELSA-N 0.000 description 2
- RMAWDDRDTRSZIR-ZLUOBGJFSA-N Ala-Ser-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RMAWDDRDTRSZIR-ZLUOBGJFSA-N 0.000 description 2
- AMIQZQAAYGYKOP-FXQIFTODSA-N Arg-Ser-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O AMIQZQAAYGYKOP-FXQIFTODSA-N 0.000 description 2
- BHQQRVARKXWXPP-ACZMJKKPSA-N Asn-Asp-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N BHQQRVARKXWXPP-ACZMJKKPSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HYKFOHGZGLOCAY-ZLUOBGJFSA-N Cys-Cys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O HYKFOHGZGLOCAY-ZLUOBGJFSA-N 0.000 description 2
- SKSJPIBFNFPTJB-NKWVEPMBSA-N Cys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CS)N)C(=O)O SKSJPIBFNFPTJB-NKWVEPMBSA-N 0.000 description 2
- HBHMVBGGHDMPBF-GARJFASQSA-N Cys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N HBHMVBGGHDMPBF-GARJFASQSA-N 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- QQLBPVKLJBAXBS-FXQIFTODSA-N Glu-Glu-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QQLBPVKLJBAXBS-FXQIFTODSA-N 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- ULXYQAJWJGLCNR-YUMQZZPRSA-N Leu-Asp-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O ULXYQAJWJGLCNR-YUMQZZPRSA-N 0.000 description 2
- VHFFQUSNFFIZBT-CIUDSAMLSA-N Lys-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N VHFFQUSNFFIZBT-CIUDSAMLSA-N 0.000 description 2
- KIZQGKLMXKGDIV-BQBZGAKWSA-N Pro-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 KIZQGKLMXKGDIV-BQBZGAKWSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- SWIQQMYVHIXPEK-FXQIFTODSA-N Ser-Cys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O SWIQQMYVHIXPEK-FXQIFTODSA-N 0.000 description 2
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 2
- ICFRWCLVYFKHJV-FXQIFTODSA-N Val-Cys-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N ICFRWCLVYFKHJV-FXQIFTODSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 1
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 1
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 description 1
- DQNLFLGFZAUIOW-FXQIFTODSA-N Arg-Cys-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O DQNLFLGFZAUIOW-FXQIFTODSA-N 0.000 description 1
- BBYTXXRNSFUOOX-IHRRRGAJSA-N Arg-Cys-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BBYTXXRNSFUOOX-IHRRRGAJSA-N 0.000 description 1
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 1
- NKTLGLBAGUJEGA-BIIVOSGPSA-N Asn-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N)C(=O)O NKTLGLBAGUJEGA-BIIVOSGPSA-N 0.000 description 1
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- 206010061736 Bronchitis bacterial Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 206010011376 Crepitations Diseases 0.000 description 1
- CLDCTNHPILWQCW-CIUDSAMLSA-N Cys-Arg-Glu Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CS)N)CN=C(N)N CLDCTNHPILWQCW-CIUDSAMLSA-N 0.000 description 1
- HEPLXMBVMCXTBP-QWRGUYRKSA-N Cys-Phe-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O HEPLXMBVMCXTBP-QWRGUYRKSA-N 0.000 description 1
- YYLBXQJGWOQZOU-IHRRRGAJSA-N Cys-Phe-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CS)N YYLBXQJGWOQZOU-IHRRRGAJSA-N 0.000 description 1
- HPZAJRPYUIHDIN-BZSNNMDCSA-N Cys-Tyr-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CS)N HPZAJRPYUIHDIN-BZSNNMDCSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 1
- FLQAKQOBSPFGKG-CIUDSAMLSA-N Glu-Cys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FLQAKQOBSPFGKG-CIUDSAMLSA-N 0.000 description 1
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 1
- DXVOKNVIKORTHQ-GUBZILKMSA-N Glu-Pro-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O DXVOKNVIKORTHQ-GUBZILKMSA-N 0.000 description 1
- PYUCNHJQQVSPGN-BQBZGAKWSA-N Gly-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN)CN=C(N)N PYUCNHJQQVSPGN-BQBZGAKWSA-N 0.000 description 1
- SABZDFAAOJATBR-QWRGUYRKSA-N Gly-Cys-Phe Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SABZDFAAOJATBR-QWRGUYRKSA-N 0.000 description 1
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 1
- DHNXGWVNLFPOMQ-KBPBESRZSA-N Gly-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)CN DHNXGWVNLFPOMQ-KBPBESRZSA-N 0.000 description 1
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 1
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 1
- PDSUIXMZYNURGI-AVGNSLFASA-N His-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC1=CN=CN1 PDSUIXMZYNURGI-AVGNSLFASA-N 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- CNNQBZRGQATKNY-DCAQKATOSA-N Leu-Arg-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N CNNQBZRGQATKNY-DCAQKATOSA-N 0.000 description 1
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 1
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- BOJYMMBYBNOOGG-DCAQKATOSA-N Lys-Pro-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BOJYMMBYBNOOGG-DCAQKATOSA-N 0.000 description 1
- RDLSEGZJMYGFNS-FXQIFTODSA-N Met-Ser-Asp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RDLSEGZJMYGFNS-FXQIFTODSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 description 1
- UTAUEDINXUMHLG-FXQIFTODSA-N Pro-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 UTAUEDINXUMHLG-FXQIFTODSA-N 0.000 description 1
- JIWJRKNYLSHONY-KKUMJFAQSA-N Pro-Phe-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JIWJRKNYLSHONY-KKUMJFAQSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- XQAPEISNMXNKGE-FXQIFTODSA-N Ser-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CS)C(=O)O XQAPEISNMXNKGE-FXQIFTODSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- KBLYJPQSNGTDIU-LOKLDPHHSA-N Thr-Glu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O KBLYJPQSNGTDIU-LOKLDPHHSA-N 0.000 description 1
- BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 1
- ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
- KZKMBGXCNLPYKD-YEPSODPASA-N Val-Gly-Thr Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O KZKMBGXCNLPYKD-YEPSODPASA-N 0.000 description 1
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 108010012004 proadrenomedullin Proteins 0.000 description 1
- 102000034567 proadrenomedullin Human genes 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006053442A DE102006053442A1 (de) | 2006-11-12 | 2006-11-12 | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
| EP07846321A EP2089718B1 (de) | 2006-11-12 | 2007-11-11 | Diagnose und risikostratifizierung von infektionen und chronischen erkrankungen der atemwege und lunge mittels provasopressin, insbesondere copeptin oder neurophysin ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2378290T3 true DK2378290T3 (en) | 2017-07-31 |
Family
ID=39277664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11170807.9T DK2378290T3 (en) | 2006-11-12 | 2007-11-11 | Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs using pro-vasopressin, especially copeptin or neurophysin II |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8158368B2 (https=) |
| EP (2) | EP2378290B1 (https=) |
| JP (3) | JP5340160B2 (https=) |
| CN (2) | CN101563613A (https=) |
| AT (1) | ATE522814T1 (https=) |
| DE (1) | DE102006053442A1 (https=) |
| DK (1) | DK2378290T3 (https=) |
| ES (2) | ES2370071T3 (https=) |
| HK (1) | HK1215731A1 (https=) |
| WO (1) | WO2008058517A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140046407A1 (en) * | 2001-08-31 | 2014-02-13 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
| EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| PL2084543T3 (pl) | 2006-10-26 | 2018-04-30 | B.R.A.H.M.S Gmbh | Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II |
| DE102007009751A1 (de) | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
| US20120329666A1 (en) * | 2009-10-05 | 2012-12-27 | Duke University | Peripheral Blood Biomarkers for Idiopathic Interstitial Pneumonia and Methods of Use |
| EP2776064A4 (en) | 2011-11-11 | 2015-08-05 | Woomera Therapeutics | PROVASOPRESSINE ANTAGONISTS AND ITS USES |
| EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| KR102511128B1 (ko) | 2022-03-31 | 2023-03-16 | (주)네오닉스 | 배터리팩 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227454C1 (de) | 1992-08-19 | 1994-02-03 | Henning Berlin Gmbh | Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens |
| DE19600875C1 (de) * | 1996-01-12 | 1997-06-26 | Brahms Diagnostica Gmbh | Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse |
| DE19847690A1 (de) | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| DE10027954A1 (de) | 1999-12-22 | 2001-06-28 | Dade Behring Marburg Gmbh | Humanes Procalcitonin, dessen Herstellung und Verwendung |
| DE50014159D1 (de) | 1999-12-22 | 2007-04-26 | Dade Behring Marburg Gmbh | Lösungen von humanem Procalcitonin |
| MXPA03004105A (es) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
| ATE491727T1 (de) * | 2002-07-16 | 2011-01-15 | Woomera Therapeutics Inc | Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen |
| WO2004059293A2 (en) * | 2002-12-24 | 2004-07-15 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| GB0401730D0 (en) * | 2004-01-27 | 2004-03-03 | Bioxell Spa | Diagnosis method |
| EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| DE102004047968A1 (de) * | 2004-10-01 | 2006-04-06 | B.R.A.H.M.S Ag | Bestimmung von Gastrokine 1 (GKN1) als Biomarker für Entzündungen und Infektionen |
| GB0508863D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Peptide |
| DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
| JP4983525B2 (ja) * | 2007-10-11 | 2012-07-25 | 住友電装株式会社 | ワイヤハーネスのプロテクタ取付構造 |
| US9229013B2 (en) * | 2009-05-05 | 2016-01-05 | B.R.A.H.M.S Gmbh | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
-
2006
- 2006-11-12 DE DE102006053442A patent/DE102006053442A1/de not_active Withdrawn
-
2007
- 2007-11-11 CN CNA2007800420148A patent/CN101563613A/zh active Pending
- 2007-11-11 US US12/514,524 patent/US8158368B2/en active Active
- 2007-11-11 WO PCT/DE2007/002037 patent/WO2008058517A2/de not_active Ceased
- 2007-11-11 DK DK11170807.9T patent/DK2378290T3/en active
- 2007-11-11 ES ES07846321T patent/ES2370071T3/es active Active
- 2007-11-11 AT AT07846321T patent/ATE522814T1/de active
- 2007-11-11 ES ES11170807.9T patent/ES2634137T3/es active Active
- 2007-11-11 EP EP11170807.9A patent/EP2378290B1/de active Active
- 2007-11-11 CN CN201510454116.7A patent/CN105092858A/zh active Pending
- 2007-11-11 EP EP07846321A patent/EP2089718B1/de active Active
- 2007-11-11 JP JP2009535559A patent/JP5340160B2/ja active Active
-
2012
- 2012-03-21 US US13/425,928 patent/US20120270245A1/en not_active Abandoned
-
2013
- 2013-01-04 JP JP2013000176A patent/JP2013083664A/ja active Pending
-
2015
- 2015-07-31 JP JP2015151852A patent/JP6170101B2/ja active Active
-
2016
- 2016-03-30 HK HK16103639.3A patent/HK1215731A1/zh unknown
- 2016-06-13 US US15/180,797 patent/US10718783B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2378290B1 (de) | 2017-05-03 |
| EP2089718B1 (de) | 2011-08-31 |
| ES2634137T3 (es) | 2017-09-26 |
| US20100041064A1 (en) | 2010-02-18 |
| ES2370071T3 (es) | 2011-12-12 |
| JP6170101B2 (ja) | 2017-07-26 |
| US8158368B2 (en) | 2012-04-17 |
| JP2010509576A (ja) | 2010-03-25 |
| EP2378290A1 (de) | 2011-10-19 |
| EP2089718A2 (de) | 2009-08-19 |
| DE102006053442A1 (de) | 2008-05-15 |
| CN101563613A (zh) | 2009-10-21 |
| WO2008058517A3 (de) | 2008-10-23 |
| WO2008058517A2 (de) | 2008-05-22 |
| JP2013083664A (ja) | 2013-05-09 |
| JP2016026286A (ja) | 2016-02-12 |
| US20120270245A1 (en) | 2012-10-25 |
| ATE522814T1 (de) | 2011-09-15 |
| US20170059583A1 (en) | 2017-03-02 |
| JP5340160B2 (ja) | 2013-11-13 |
| CN105092858A (zh) | 2015-11-25 |
| US10718783B2 (en) | 2020-07-21 |
| HK1215731A1 (zh) | 2016-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10718783B2 (en) | Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin II | |
| US8465941B2 (en) | Procalcitonin-based diagnosis of infections or inflammatory diseases of the respiratory tract in a patient with heart failure | |
| JP5185460B2 (ja) | ｉｎｖｉｔｒｏプロカルシトニン・アッセイ方法 | |
| ES2388055T3 (es) | Diagnóstico y estratificación de riesgo mediante NT-proET-1 | |
| CN110431425B (zh) | proADM作为指示不良事件的标志物 | |
| EP3497450B1 (en) | Histones and/or proadm as markers indicating organ dysfunction | |
| CN109564225A (zh) | 作为指示不良事件的标志物的组蛋白和/或proADM | |
| JP2010509576A5 (https=) | ||
| CN116640843A (zh) | 肝硬化相关肌肉减少症的生物标志物 | |
| JP6250351B2 (ja) | 好酸球性気道炎症に関する情報の取得方法およびそのような情報を取得するためのマーカー | |
| CN111065922A (zh) | 肾上腺髓质素原作为危重病患者的肾脏替代治疗的指标 | |
| HK1135183A (en) | Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin ii | |
| JP7687635B2 (ja) | Ｃｏｐｄ指標値の測定方法 | |
| JP7818217B2 (ja) | 呼吸器感染症の重篤度判別方法および試薬 | |
| ES2807960T3 (es) | Método para diagnosticar infecciones pulmonares postoperatorias en pacientes que se sometieron a cirugía | |
| HK1137807B (en) | Diagnosis of infections or inflammatory diseases of the airways and lungs associated with heart failure | |
| JP2024113271A (ja) | 癌の腫瘍マーカー | |
| WO2022091793A1 (ja) | 糞便由来タンパク質を用いた膵臓がんバイオマーカーの開発 | |
| CN118518881A (zh) | 用于诊断宫颈癌肺转移的生物标志物、试剂盒及其应用 | |
| HK40030378A (zh) | 基於pro-adm的抗生素疗法指导 | |
| HK40017069B (en) | Proadm as marker indicating an adverse event | |
| HK40029189A (en) | Proadrenomedullin as indicator for renal replacement therapy in critically ill patients |